Microfluidic Isolation of Microvesicles from Serum in GlioblastomaTuesday, 25 March 2014 at 16:00 Add to Calendar ▼2014-03-25 16:00:002014-03-25 17:00:00Europe/LondonMicrofluidic Isolation of Microvesicles from Serum in GlioblastomaCirculating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com Microvesicles (MVs) released from cancer cells into the bloodstream contain genetic information about the primary tumor. These MVs have the potential to be used to guide treatment in glioblastoma patients, but can be challenging to reliably assay due to the heterogeneous population of MVs released from normal cells. We have taken a microfluidic approach to isolate these tumor derived MVs from human serum, using affinity based capture. Specifically, a microfluidic chaotic mixer is used to direct the MVs to the antibody coated surface of the device. This approach increases our sensitivity of detection of oncogenic mutations, while being cost effective. Our MV capture and subsequent RNA analysis was validated using tumor MVs from a glioblastoma cell line spiked into healthy human serum. Our data demonstrates that tumor-derived MVs can be selectively captured from serum, providing a less invasive method to obtain genetic information about the patient’s tumor. |